Online inquiry

IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12297MR)

This product GTTS-WQ12297MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Merkel cell carcinoma (MCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12297MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11981MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ13362MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ10580MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ8154MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ10221MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4494MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ2757MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ5920MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CK-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW